Hematologic Malignancies

Hematologic Malignancies

Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.

A phase III trial of vosaroxin failed to meet its primary overall survival endpoint in patients with first relapsed or refractory acute myeloid leukemia.

Myeloma patients treated with melphalan prior to transplant had reductions in chemo-induced nausea/vomiting when given granisetron/dexamethasone and aprepitant.

In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.

A regimen of gemcitabine/dexamethasone/cisplatin was as effective and less toxic than the current standard of care for treating relapsed, refractory lymphoma.

Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.

Patients with non-high-risk APL can achieve better clinical outcomes when treated with ATRA plus arsenic trioxide compared with ATRA plus chemotherapy, a new study found.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.